For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

We use cookies to make our site as useful as possible.

Our Cookie Policy explains how you can opt-out of the cookies we use.

If you continue without changing your cookie settings, we'll assume you’re happy with this.

Continue Continue

United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Diagnostic & Therapeutic Solutions
    Custom solutions & partnerships

    Custom antibody development and commercial partnerships to advance your diagnostic and therapeutic discovery.

    Create custom solutions with us

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Supporting our customers and employees during the COVID-19 pandemic. Read more

Response and resistance in immuno-oncology

Related

  • Immuno-oncology resources
    • Tools for immuno-oncology research
      • Powering multiplex imaging
        • New product releases for immuno-oncology
          • New Directions in Immuno-oncology: Response and Resistance conference (February 2021)

            Published January 25, 2021

            Find resources and tools for understanding tumor-specific response and resistance to cancer immunotherapies.  

            Overview

            • What is immunotherapy?
            • The role of the immune system
            • Flexible, validated research solutions
              • Key targets involved in tumor resistance: STING, IDO1, and VISTA
                • STING
                • IDO1
                • VISTA
              • New flow cytometry antibodies to support the studies of live cells
              • Antibody panels to increase your chance of success
            • Advancing immuno-oncology research, together

            ​


            ​What is immunotherapy?

            Immunotherapy is a revolutionary approach to cancer treatment that helps the immune system recognize and attack cancer cells1. Current immunotherapies include immune checkpoint inhibitors, CAR-T cells, vaccines, and monoclonal antibodies that, for a subset of patients, has provided long-term, durable responses to a variety of cancers. However, some patients fail to respond to treatment at all, while others achieve a limited response followed by tumor progression. Therefore, understanding the factors that contribute to an effective response and determining mechanisms of resistance will be critical as immunotherapies are applied more broadly2.

            The role of the immune system

            The function of the immune system is to protect against disease and clear the body of unhealthy, ailing cells, including cancer cells. T cells selectively recognize and kill pathogens and unhealthy cells by orchestrating a coordinated immune response, including innate and adaptive responses.  However, various cancers have unique triggers that result in evasion from the immune response, making them more resistant to immunity3.

            Immunotherapy involves strengthening the cancer patient’s immune system by improving its tumor recognition ability or providing a missing immune effector function to provide durable, adaptable cancer control4,5.

            ​Flexible, validated research solutions

            Discover reagents to novel targets and emerging multiplex technologies to support your immuno-oncology research and assay development. Here we’ve highlighted key products so you can easily select the best one. ​​


            Key targets involved in tumor resistance: STING, IDO1, and VISTA 


            STING

            ​Stimulator of interferon genes (STING) is a signaling molecule that plays a crucial role in controlling the transcription of many host defense genes such as pro-inflammatory cytokines and chemokines. Previous studies into the roles of STING in immunomodulation showed the potential of STING agonists as cancer therapeutics to activate antitumor immune responses6.​

            Product highlight



            ​Recombinant STING (Anti-TMEM173 antibody [EPR13130-55] (ab239074)

            Rabbit monoclonal to STING

            Suitable for: WB, ICC/IF, IP, IHC-P, Flow Cyt

            Reacts with: Human

            View the full range of products to STING



            IDO1

            ​Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into kynurenine. The resulting depletion of tryptophan and subsequent increase in kynurenine exert important immunosuppressive functions, thus making IDO1 a potential therapeutic opportunity in cancer immunotherapy7. ​

            ​Product highlight




            Recombinant IDO1 (anti-Indoleamine 2, 3-dioxygenase)  antibody [EPR20374] (ab211017)

            Rabbit monoclonal to Indoleamine 2, 3-dioxygenase

            Suitable for: WB, ICC/IF, Flow Cyt, IP, IHC-P

            Reacts with: Human

            View all products to IDO1 here


            ​

            VISTA

            V-domain Ig suppressor of T cell activation (VISTA) is a novel checkpoint inhibitor that is a promising target for immunotherapeutic intervention due to its role in regulating innate and adaptive immune responses8.

            Product highlight



            ​​